欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
Farage人B淋巴瘤细胞系 (STR鉴定)
英文名:Farage
货号:ZQ0632
价格:¥1200.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

Farage人B淋巴瘤细胞系 (STR鉴定)

¥1200.00
+

Farage人B淋巴瘤细胞系专用培养基

¥350.00 ¥450.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1550 ¥2450.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

Farage人B淋巴瘤细胞系

货号

ZQ0632

产品介绍

Farage是一种B淋巴细胞系,法拉奇细胞系是于1990年从弥漫性大细胞非霍奇金淋巴瘤(DLCL)成年女性患者的淋巴结活检中培养建系。由于其独特的特性和对各种刺激的反应,这一细胞系在免疫学研究中尤为宝贵。法拉奇细胞在悬浮培养中生长,并且不表达表面或细胞质免疫球蛋白,突出了它们在研究免疫反应时的实用性,因为这些蛋白质不会干扰实验。


当用白细胞介素-4(IL-4)处理时,法拉奇细胞会增加包括CD23、CD54和CD58在内的几个标记物的表达,同时减少CD21、CD22和CD38的水平。这种表面标记物的调节表明IL-4在影响B细胞行为中的作用,并为探索B细胞中的信号传导途径和调控机制提供了有用的模型。此外,对佛波酯12-肉豆蔻酸酯13-乙酸酯(PMA)的处理反应,导致CD21和CD23的下调,进一步支持了其在研究B细胞中激酶驱动的信号传导中的应用。

法拉奇细胞中缺乏末端脱氧核糖核酸转移酶(TdT)和重组激活基因(RAG-1和RAG-2)证实了它们作为成熟B细胞而非前B细胞的分类。这一特点对于针对B细胞发育或功能的成熟阶段的研究至关重要。此外,这些细胞中存在Epstein-Barr病毒(EBV),可以利用这一点在研究病毒与宿主细胞机制的相互作用中,特别是在淋巴细胞的致癌过程中。

种属

性别/年龄

女/成人

组织

淋巴结 

疾病

淋巴瘤;非霍奇金氏B细胞

细胞类型

肿瘤细胞

形态学

成淋巴细胞

生长方式

悬浮

倍增时间

大约48小时 

培养基和添加剂

RPMI1640(品牌:中乔新舟  货号:ZQ-200+10%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZQ-220

生物安全等级

BSL-2

STR位点信息

Amelogenin:X;
CSF1PO:11,12;
D2S1338:24,25;
D3S1358 :14,18;
D5S818:12;
D7S820:12;
D8S1179 :12;
D13S317:11,13;
D16S539:11,12;
D18S51:12,13;
D19S433:14;
D21S11:29;
FGA :20,23;
Penta D:9,12;
Penta E:7,18;
TH01:8,9;
TPOX:9;
vWA:14,15; 

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

ATCC; CRL-2630 

供应限制

仅供科研使用

货号

ZQ0632

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


论文标题: Knockdown of long non‑coding RNA ANRIL inhibits the proliferation and promotes the apoptosis of Burkitt lymphoma cells through the TGF‑β1 signaling pathway
DOI: 10.3892/mmr.2020.11785
发表时间: 2020-12-15
期刊: Molecular Medicine Reports
影响因子: 2.1
货号: ZQ0632
产品名称: Farage cells

原文链接: https://www.spandidos-publications.com/10.3892/mmr.2020.11785



DOI=10.3109/10428199209053591
Ben-Bassat H., Polliack A., Shlomai Z., Kohn G., Hadar R., Rabinowitz R., Leizerowitz R., Matutes E., Buchier V., Brok-Simoni F., Okon E., Livni N., Schlesinger M.
Farage, a novel early B cell lymphoma cell line with trisomy 11.
Leuk. Lymphoma 6:513-521(1992)


PubMed=9172815; DOI=10.3109/10428199609093448
Baruch M., Hochberg M., Gabay C., Ben-Bassat H., Shlomai Z., Laskov R.
Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line ('Farage') lacking the ability to produce immunoglobulin polypeptide chains.
Leuk. Lymphoma 21:485-495(1996)


DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)


PubMed=11378582; DOI=10.3109/10428190109060355
Rabinowitz R., Yu Y.-M., Belov E., Shubinsky G., Ben-Bassat H., Schlesinger M.
Regulation of the expression of CD45 isoforms in the Farage human B cell lymphoma line and its 10.6.1 subline.
Leuk. Lymphoma 41:643-654(2001)


PubMed=19278952; DOI=10.1182/blood-2009-01-202028
Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Blood 113:6681-6690(2009)


PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=20628145; DOI=10.1182/blood-2010-05-282780
Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Blood 116:3268-3277(2010)


PubMed=23292937; DOI=10.1073/pnas.1205299110
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)


PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)


暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号